Previous 10 | Next 10 |
BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Sam Lee, Ph.D., Pre...
- Presentation on Friday, October 4 th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel anti...
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study demonstrated favorable pharmacokinetic and ADMET profiles of PB2 inhibitors - BOTHELL, WA, Sept. 03...
Noteworthy events during the week of August 25 - 31 for healthcare investors. More news on: Daiichi Sankyo Company, Limited, Intellipharmaceutics International Inc., Nektar Therapeutics, Healthcare stocks news, , Read more ...
BOTHELL, WA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it will present pre...
Cocrystal Pharma (NASDAQ: COCP ): Q2 GAAP EPS of -$0.05. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure additional strategic partnerships across pipeline – BOTH...
- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest HepC virus carrier populations in the world BOTHELL, WA, May 20, 2019 (GLOBE NEWSWIRE...
Cocrystal Pharma (NASDAQ: COCP ): Q1 Net income of $2.97M. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Company is well positioned to achieve multiple corporate, clini...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...